N-Zyme Biomedical Begins Phase 2 Trial of First Pepsin Inhibitor for Reflux Disease

Source Summary

WAUWATOSA, Wis. & NEWARK, Del.--(BUSINESS WIRE)-- #Biotech--N-Zyme Biomedical, a clinical-stage biotechnology company developing a novel class of therapeutics targeting pepsin in reflux disease, today announced the initiation of its Phase 2 clinical trial to evaluate its lead pepsin inhibitor candidate for the treatment of laryngopharyngeal reflux (LPR). The trial represents a key milestone in the development of what is believed to be the first therapeutic approach specifically designed to inhibit pepsin,